Immuno-oncology – Endpoints News

Ticker	Current Price	Change	Graph
IBB	118.55	0.74 (0.62%)
XBI	95.54	1.62 (1.67%)

Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal

by John Carroll — on September 13, 2018 06:31 AM EDT

Bristol-Myers will sell Opdivo in China at half of US cost, setting precedent for checkpoint wave — report

by Amber Tong — on August 22, 2018 08:44 AM EDT
Updated: 01:34 PM

$60M in, AbbVie is triggering a $625M-plus plan to develop a new immuno-oncology drug that is going after GARP

by John Carroll — on August 22, 2018 06:13 AM EDT

FDA gives Merck ‘real-time’ OK for Keytruda, offering a peek at the latest extension of the agency’s data express highway

by John Carroll — on August 21, 2018 06:13 AM EDT

After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market

by John Carroll — on July 27, 2018 07:38 AM EDT
Updated: 07:40 AM

Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test

by John Carroll — on July 22, 2018 08:01 PM EDT
Updated: 08:08 PM

Roche’s IMpower 132 hits on progression-free survival, but Merck remains in control — for now — on frontline lung cancer

by John Carroll — on July 19, 2018 06:25 AM EDT
Updated: 11:04 AM

Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more

by Amber Tong — on July 12, 2018 06:01 AM EDT

Nektar wants everyone to stay calm as they carry on with NKTR-214, but #ASCO18 spurs a stampede

by John Carroll — on June 3, 2018 04:56 PM EDT
Updated: June 4, 2018 02:56 PM

PhRMA’s new report counts each cancer drug in the US pipeline, which has now swelled to over 1,000 in the clinic

by Brittany Meiling — on May 30, 2018 10:45 AM EDT

Merck crushes Keynote-407 study in frontline lung cancer, hitting co-primaries and setting up another quick OK

by John Carroll — on May 23, 2018 07:09 AM EDT
Updated: 07:17 AM

FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers

by John Carroll — on May 7, 2018 06:17 AM EDT

Playing the long game in I/O, J&J inks $1.04B deal to buy oncolytic virus platform biotech BeneVir

by Amber Tong — on May 2, 2018 09:25 AM EDT
Updated: 10:26 AM

Leena Gandhi steps out of Keytruda spotlight and into a top research job at I/O laggard Eli Lilly

by John Carroll — on April 30, 2018 08:49 AM EDT
Updated: 08:54 AM

Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint

by John Carroll — on April 30, 2018 06:37 AM EDT

#AACR18: Roche spotlights promising subgroup responses for lung cancer combo with Tecentriq

by John Carroll — on April 16, 2018 04:38 PM EDT

#AACR: Merck spotlights pivotal Keytruda/chemo data, hoping to break down skepticism to its frontline lung cancer duo

by John Carroll — on April 16, 2018 09:30 AM EDT
Updated: 10:00 AM

#AACR: Bristol-Myers tunes out static, broadcasts impressive results for Opdivo/Yervoy lung cancer combo

by John Carroll — on April 16, 2018 09:08 AM EDT
Updated: 10:00 AM

#AACR18 round 1: Merck takes a direct swing at Bristol-Myers with adjuvant melanoma data for Keytruda

by John Carroll — on April 15, 2018 09:30 AM EDT
Updated: 12:25 PM

Penn team spotlights a pilot ovarian cancer trial and survival rates for a personalized cancer vaccine

by Amber Tong — on April 13, 2018 07:56 AM EDT
Updated: 08:02 AM

Category: Immuno-oncology